Clinical trials: Differentiation
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses.
- Trial name
- NCT03487263
- Testing
- IC14
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Implicit Bioscience
Autoimmune Diseases
CAR-T Therapy for Refractory Autoimmune Diseases
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases.
- Trial name
- NCT07059169
- Testing
- JY231 (JY231 injection)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- LiangZou
Leukemia
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them…
- Trial name
- NCT00006045
- Testing
- lintuzumab, cytarabine, etoposide
- Where
- 59 sites in United States, Belgium and 5 more
- Sponsor
- Facet Biotech
Breast Cancer
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to…
- Trial name
- NCT00291759
- Testing
- Tamoxifen, Anastrozole
- Where
- 52 sites in Austria
- Volunteers
- 3,858 people
- Sponsor
- AstraZeneca
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer
Differentiated Thyroid Cancer
rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid Cancer
This is a randomized, open, parallel controlled, multi-center clinical trial; 120 subjects were randomly assigned to the test group and the control group according to 3:1.
- Trial name
- NCT04447183
- Testing
- Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH), radioactive iodine
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Neuroendocrine (NE) Tumors, Advanced NET of GI Origin
AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
A phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours.
- Trial name
- BHARAT-3 (NCT07640737)
- Testing
- AUR103 Calcium
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aurigene Discovery Technologies Limited
Thyroid Carcinoma
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period.
- Trial name
- JPMS-DTC (NCT02185560)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 453 people
- Sponsor
- Bayer
Radioiodine-refractory Differentiated Thyroid Cancer
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R…
- Trial name
- NCT07770074
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-Cell Lymphoma, B-Cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07881211
- Testing
- BG-T0050
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Angina Pectoris
Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine
This study used a multicenter, prospective cohort study. According to whether they received TCM treatment and the degree of exposure to TCM, the cohorts were divided into strong TCM exposure group, TCM exposure group, weak TCM…
- Trial name
- NCT05482009
- Testing
- Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with…
- Trial name
- NCT06419634
- Testing
- BMS-986497, Azacitidine, Venetoclax
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody in patients with DLBCL
- Trial name
- ALEXANDER (NCT03287817)
- Testing
- AUTO3
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Autolus Limited
DTC - Differentiated Thyroid Cancer
A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer
This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated…
- Trial name
- NCT07287748
- Testing
- [211At]NaAt
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Alpha Fusion Inc.
Arrhythmias, Cardiac
Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion
This research study is a prospective, single-center, feasibility study designed to assess the possibility to detect hemodynamic changes during tachycardia episodes using tissue perfusion.
- Trial name
- NCT01088308
- Testing
- High rate atrial and vetricular stimulation, Ventricular Tachycardia induction
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Medtronic BRC
HIV Infections
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the…
- Trial name
- NCT00672191
- Testing
- AGS-004
- Where
- 12 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Argos Therapeutics
Thyroid Cancer
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily…
- Trial name
- NCT02702388
- Testing
- Lenvatinib
- Where
- 101 sites in United States, Australia and 14 more
- Volunteers
- 241 people
- Sponsor
- Eisai Inc.
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Acute Respiratory Tract Infection
Differentiation of Upper and Lower Respiratory Tract Infections Using Automated Lung Sound Analysis With LungPass Device
This observational study evaluates whether lung sound analysis with LungPass device can be used to differentiate upper and lower respiratory tract infections (URTI and LRTI)
- Trial name
- NCT05175612
- Testing
- Lung auscultation with LungPass device (electronic auscultation)
- Where
- Belarus
- Volunteers
- 400 people
- Sponsor
- Healthy Networks